CRL

NYSE

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Health Care, Life Sciences Tools & Services

$267.49

close 7 Aug 2026

+79.61%

52-week change

$12.77B

market cap

$144.26

$268.00

52-week range

Expected price

$5.16 – $6.31

Current price

$267.49

Signal

Could be overvalued

A historical-multiple reference, never a fair-value claim. The band uses only data public at each date and ends at the latest month — no forward estimates.

Current multiples

P/E (TTM)-55.73x

P/S (TTM)3.19x

P/B4.50x

EV/EBITDA (TTM)39.17x

FCF yield (TTM)2.90%

PEG (TTM, GAAP)—

Context

P/E, own 5-year average75.50x

P/E, sector median29.65x*

Price at 5-year median P/E—*

Forward — analyst consensus

Forward P/E (FY2026)23.76x*

Forward P/E (FY2027)21.18x

Forward PEG1.95*

Consensus EPS FY2026 (16 analysts)$11.26

EPS growth (FY2026→FY2027)12.19%

Revenue growth (FY2026)-2.66%

Street view

Price target (mean)$267.71*

Target upside0.08%

Ratings (buy / hold / sell)13 / 2 / 1

FY2026 EPS revisions, 30d (up / down)3 / 0

5-year history

Dashed line: average of month-end values

P/E (TTM)

P/S (TTM)

P/B

FCF yield (TTM)

period to 27 Jun 2026, filed 5 Aug 2026, close 7 Aug 2026

Discounted cash flow

Ten projected years plus a perpetuity, prefilled from filings — a model to argue with, never a fair-value claim.

Free cash flow, last ten years and TTM

5Y CAGR +6.41%10Y CAGR +7.85%

Assumptions

Growth rate, years 1–10%

Perpetual growth%Discount rate%

Base FCF$M

As filed — not assumptions

Current price$267.49

Cash & equivalents$192.03M

Total debt$2.63B

Shares outstanding47.73M

Result

DCF price per share$145.41

Current price$267.49

Margin of safety-45.64%

PV of years 1–10$3.42B

PV of terminal value$5.95B

Equity value$6.94B

Market-implied growth+12.62%

Projected FCF, years 1–10

Hover for PV and growth

Projection detail

Override growth for any year; blank years use the uniform rate

Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	Terminal
Growth, %											2.5
FCF	$394.37M	$419.64M	$446.54M	$475.17M	$505.63M	$538.04M	$572.52M	$609.22M	$648.27M	$689.83M	$12.86B
PV	$365.15M	$359.78M	$354.48M	$349.26M	$344.12M	$339.05M	$334.06M	$329.14M	$324.30M	$319.52M	$5.95B

period to 27 Jun 2026, filed 5 Aug 2026, close 7 Aug 2026